Article

Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF)

2026-05-18

Abstract excerpt

<h4>Aims</h4> Heart failure with preserved ejection fraction (HFpEF) afflicts millions annually and current treatments provide symptomatic relief. Here, we investigate the therapeutic potential of synthetic human Relaxin-2 (RLX) at reversing diastolic dysfunction (DD) and reducing arrhythmia vulnerability. <h4>Methods and Results</h4> Male ZSF1 rats were placed on a normal diet (ND, N=10 controls) or a high-fat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a933fd15-5218-5fac-af1e-b199649e3cc6
DOI: 10.64898/2026.05.14.725229

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF)DOI 10.64898/2026.05.14.725229Read

Synthetic Growth Hormone-Releasing Hormone Agonist as Novel Treatment for Heart Failure with Preserved Ejection FractionSemantic proximity Read

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read

Cardiometabolic Phenotype in HFpEF: Insights from Murine ModelsSemantic proximity Read

Repurposing Nintedanib for Pathological Cardiac Remodeling and DysfunctionSemantic proximity Read

Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials.Semantic proximity Read

The cardiac enigma: current conundrums in heart failure researchSemantic proximity Read

Primary heart failure with preserved ejection fraction: The intertwined pathophysiology and treatment of some of the most relevant phenotypes.Semantic proximity Read

Physiological or pathological--a role for relaxin in the cardiovascular system?Semantic proximity Read

Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches.Semantic proximity Read

β₃-Adrenergic Signaling in Heart Failure: A Stage-Dependent Double-Edged SwordSemantic proximity Read

Optimized protocols for commonly-used murine models of heart failure with preserved ejection fractionSemantic proximity Read

Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trialSemantic proximity Read